HPV mRNA testing in cervical cancer screening
- PMID: 36174617
- DOI: 10.1016/S1470-2045(22)00486-7
HPV mRNA testing in cervical cancer screening
Conflict of interest statement
PGR conducted negotiations with Roche, Hologic, and Becton Dickinson to obtain reagents at reduced price or for free as the principal investigator of an independent study, funded by the Italian Ministry of Health. MR has received financing from Public Health England for the epidemiological evaluation of cervical screening studies, is a member of various expert groups providing advice to the English Cervical Screening Programme, and has attended meetings with various HPV assay manufacturers (unpaid).
Comment in
-
HPV mRNA testing in cervical cancer screening - Authors' reply.Lancet Oncol. 2022 Oct;23(10):e437. doi: 10.1016/S1470-2045(22)00551-4. Lancet Oncol. 2022. PMID: 36174618 No abstract available.
Comment on
-
Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis.Lancet Oncol. 2022 Jul;23(7):950-960. doi: 10.1016/S1470-2045(22)00294-7. Epub 2022 Jun 13. Lancet Oncol. 2022. PMID: 35709810
